This study tests a medicine called tezepelumab to see if it helps adults with moderate to very severe COPD (Chronic Obstructive Pulmonary Disease). COPD is a lung disease that makes it hard to breathe. The study is "randomized," meaning participants are chosen by chance, and "double-blind," meaning neither the doctors nor the participants know who gets the real medicine or a "placebo," a fake treatment. The study lasts up to 76 weeks with monthly injections and a 12-week follow-up without treatment. To join, you should be 40-80 years old, have had COPD for at least a year, and have had some serious flare-ups in the past year. Smokers or former smokers with a certain smoking history can join.

• Participation requires monthly visits for up to 76 weeks.
• Eligibility includes specific age, smoking history, and COPD severity.
• Participants must not have asthma or other lung diseases.